ResearcherPage View Count

Geo Map
Region#
AS - Asia5820
NA - North America2379
EU - Europe1535
HKU - The University of Hong Kong1212
OC - Oceania96
AF - Africa94
SA - South America10
UND - Undefined157
Total11303
Country#
CN - China3212
US - United States2329
HKU - The University of Hong Kong1212
HK - Hong Kong1174
KR - Republic of Korea953
GB - United Kingdom678
FR - France300
IE - Ireland161
IN - India160
SG - Singapore157
OTH - Others967
Total11303
City#
The University of Hong Kong1212
Ashburn1080
Beijing785
Central District454
Nanjing376
Central318
San Ramon230
Shenzhen191
Wuhan174
Shanghai171
Others6312
Total11303
Use of PET-CT scan as tool of treatment response evaluation for solitary spine metastasis after SBRT66
Toxicity outcome of endorectal brachytherapy boost in medically inoperable patients28
PD-L1 expression in patients with anaplastic thyroid carcinoma: prevalence and outcome75
A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening49
PD-L1 expression in CCs of esophageal carcinoma patients20
Feasibility study of intraperitoneal docetaxel combined with intravenous cisplatin and oral S-1 for gastric cancer patients with peritoneal carcinomatosis89
Pre-treatment EBV DNA differentiates different stages of undifferentiated carcinoma of the nasopharynx106
The impact of complete metabolic response in the treatment of metastatic colorectal cancer88
Opioid in management of breathlessness in patients with cancer68
Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma49
Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer - Will the Pendulum Swing23
The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy: Asian perspectives in the immunotherapy era13
Capecitabine but not 5-FU worsened hepatosplenomegaly and liver function when used with oxaliplatin and cetuximab as first-line treatment in K-ras wild-type metastatic colorectal cancer113
Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy213
Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma72
Prospective Evaluation of the G8 Screening Tool for Predicting Treatment-related Toxicities in Chinese Elderly Cancer Patients24
Addition of cetuximab to oxaliplatin-based chemotherapy on liver and spleen size and thrombocytopenia in patients with metastatic colorectal cancer129
Treatment Strategy In Stage Ivb Anaplastic Thyroid Carcinoma, A Single Center Experience138
Impact of intravenous contrast used in computed tomography on radiation dose to carotid arteries and thyroid in intensity-modulated radiation therapy planning for nasopharyngeal carcinoma.37
Optimal Sequencing in Third Line mCRC to Extend Survival12
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening320
Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong135
Early-stage Nasopharyngeal Carcinoma97
Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy114
Integration of Ramucirumab into Our Practice29
Beyond 2nd Line Treatment in Metastatic Colorectal Cancer: Evidence and Perspectives36
Immune-related Endocrine Dysfunction in Chinese: a single tertiary centre experience20
Predicting liver and lung metastasis in esophageal cancer: does the site of primary tumor really matter?19
The BMP antagonist, SOSTDC1, restrains gastric cancer progression via inactivation of c-Jun signaling23
From complexity to simplicity: best level of evidence for metastatic colorectal cancer.36
Real-world Scenario: CROSS Regimen as Preoperative Therapy for Oesophageal Squamous Cell Carcinoma39
Appropriate timing for surgery after neoadjuvant chemoradiation for esophageal cancer79
Cetuximab beyond progression in Kras wild-type metastatic colorectal cancer159
Quality of end-of-life care of advanced cancer patients in mainland China—a retrospective cohort of 441 hospital-death in a public funded comprehensive hospital17
Complementary role of circulating tumor cell and cfDNA improves detection of minimal residual disease in metastatic nasopharyngeal carcinoma82
Cetuximab in KRAS wild-type mCRC: Oral and Infusional Fluoropyrimidine in Clinical Practice24
5-Year Results of the Prognostic Roles of Serial Post-Intensity-Modulated Radiation Therapy Undetectable Plasma EBV DNA for Non-Metastatic Nasopharyngeal Carcinoma115
Radiation recall after capecitabine in a patient with recurrent nasopharyngeal carcinoma: a case report50
Nasopharyngeal Cancer55
Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors140
Adjuvant S-1 chemotherapy after curative resection of gastric cancer62
Chemotherapy at end-of-life: an integration of oncology and palliative team96
A patient with gastric adenocarcinoma and extensive metastases74
The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment65
Expert view: cetuximab in mCRC53
Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma126
Real‐world treatment patterns and outcomes in refractory metastatic colorectal cancer35
Personalised Treatment in Metastatic Colorectal Cancer23
Dosimetric predictors of Hypothyroidism after Radical Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma80
The addition of pretreatment plasma Epstein–Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification159
Use of intravoxel incoherent motion magnetic resonance imaging in differentiation between recurrent nasopharyngeal carcinoma and post-chemoradiation fibrosis: initial experience49
Clinical Outcomes and Progression Pattern of Patients with Complete Metabolic Response by 18F-FDG PET-CT in Patients with Metastatic Colorectal Carcinoma65
Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci13
Cetuximab rechallenge: an additional therapeutic option in mCRC53
Nasopharyngeal carcinoma: comparison of diffusion and perfusion characteristics between different tumour stages using intravoxel incoherent motion MR imaging.80
Effect of Titanium Hardware on Radiation Dosimetry in Postoperative Proton versus Photon Spinal Stereotactic Body Radiation Therapy after Surgical Decompression for Spinal Cord Compression75
Comparison of post-treatment plasma EBV DNA with nasopharyngeal biopsy in patients after radical (chemo) radiotherapy for non-metatatic nasopharyngeal cancer120
Radiotherapy for Thoracic Esophageal Squamous Cell Carcinoma25
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer150
Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes20
To feed or not to feed: artificial nutrition/hydration in the terminally-ill181
ORAI2 Promotes Gastric Cancer Tumorigenicity and Metastasis Through PI3K/Akt Signaling and MAPK-dependent Focal Adhesion Disassembly19
Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma45
Radiotherapy for Cervical Esophageal Squamous Cell Carcinoma27
Prospective study on oral candidal infection after intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma: correlation with the radiation dose to the parotids50
Neoadjuvant Chemoradiotherapy Using Cisplatin and 5-Fluorouracil (PF) Versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): A Propensity Score-Matched Study32
Leukocyte telomere length associates with nasopharyngeal carcinoma risk and survival in Hong Kong Chinese82
Treatment Regret in Long-term Survivors of Nasopharyngeal Carcinoma Treated with Radical Radiotherapy53
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial44
Target Therapy for Esophageal Adenocarcinoma66
Incorporating Multikinase Inhibitor into the Treatment of mCRC: Focus on Regorafenib: Local Experience and Case Sharing19
Evolution of Neoadjuvant Chemoirradiation in Rectal Cancer40
Clinical usefulness of CTC enumeration, EBV DNA, and PET imaging for metastatic Nasopharyngeal carcinoma51
Treatment regret amongst survivors of nasopharyngeal cancer (NPC) treated with radical radiotherapy46
Utility of Intravoxel Incoherent Motion MR Imaging in Characterisation of Nasopharyngeal Carcinoma67
Radiotherapy for Esophageal Adenocarcinoma67
Anti-Angiogenesis in mCRC: Aligning Global Perspective and Local Experience20
Biological tumor volume (BTV) as a predictor for local control in nasopharyngeal carcinoma (NPC)106
Predictors of treatment outcome in patients treated with radical chemoradiotherapy for stage III Non-small Cell Lung Cancer61
New hope for advanced nasopharyngeal cancer—an Epstein-Barr virus-driven endemic malignancy?70
Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting50
A Comparison of Cetuximab with Oral versus Infusional Fluoropyrimidine in Chinese Patients in the Community Setting38
Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis60
Evaluation Of The Global Pattern Of Cancer Survival And The Correlation With Healthcare Expenditures11
PD-L1 hotspot in tumor-infiltrating lymphocytes of radically treated esophageal squamous cell carcinoma: Pattern of recurrence and long-term clinical outcomes116
Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma – How far have we achieved?53
S-1 Versus S-1 Plus Cisplatin as First-line Treatment for Metastatic Gastric Cancer49
Atezolizumab With Or Without Cobimetinib Versus Regorafenib In Previously Treated Metastatic Colorectal Cancer (imblaze370): A Multicentre, Open-label, Phase 3, Randomised, Controlled Trial32
Perioperative Treatment for Gastric Cancer - Oncologist’s Perspectives35
Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma100
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib64
Establishment of a large-scale drug sensitivity screening platform on gastric cancer organoid cultures with potential to guide treatment153
Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma92
Metastatic colorectal cancer: optimizing treatment with anti-EGFR monoclonal antibody52
Manual contouring based volumetric evaluation for colorectal cancer with liver limited metastases: a comparison with RECIST120
Gastric Cancer - From Aetiology to Management: Differences Between the East and the West35
Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma79
Implementation of neoadjuvant chemotherapy for breast cancer in HKUSZH: A real-world setting with Multiple Disciplinary Team89
Maximizing treatment exposure in metastatic colorectal cancer47
A tale of two cities in China: Hong Kong and Shenzhen92
Systemic Therapy for Esophageal Squamous Cell Carcinoma31
Clinical case discussion on esophageal cancer15
Kras Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab at First-Line40
Blood telomere length associates with NPC risk and survival55
Aflibercept-induced Nephrotic Syndrome63
Neoadjuvant chemoradiotherapy in locoregionally advanced squamous cell cancer of the oesophagus: beyond CROSS?60
Intravoxel incoherent motion MR imaging in nasopharyngeal carcinoma: Comparison and correlation with dynamic contrast enhanced MR imaging70
Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma77
Serial early post-intensity-modulated radiation therapy (IMRT) undetectable plasma EBV DNA to predict long-term outcomes in nasopharyngeal cancer (NPC)81
Whole-brain radiotherapy with simultaneous integrated boost using volumetric modulated arc therapy (VMAT) for patients of recursive partitioning analysis (RPA) class I and II suffering from 1-3 brain metastases102
Real Life experiences of regorafenib in refractory mCRC - Hong Kong Experience and Case Sharing26
Gefitinib-induced toxic epidermal necrolysis in a patient with metastatic non-small cell lung cancer94
Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population25
Bevacizumab after cetuximab failure in Kras wild-type metastatic colorectal carcinoma172
Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma159
Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma25
Safety and Efficacy of S-1 monotherapy and S-1-Cisplatin combination chemotherapy in the first line setting of metastatic gastric cancer - Retrospective analysis in a tertiary referral centre16
Anti-EGFR Treatment in mCRC: Which Patient and How in 201618
The most optimal induction chemotherapy regimen for loco-regionally advanced nasopharyngeal carcinoma: A network meta-analysis21
Challenging Case Workshop in Gastrointestinal Cancers: Metastatic CRC 2nd Line (Kras WT)21
Lymphopenia Association with Planning Target Volume and Lung V5 and its effect on survival of esophageal cancer receiving neoadjuvant chemo-radiation with Dutch CROSS regime95
Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma74
Effective Dose to Lymphocytes Predicts Lymphopenia and May Predict Survival in Patients Treated with CROSS Regimen in Patients with Squamous Cell Carcinoma of Esophagus30
Colorectal Cancer in Daily Practice: Challenges and Opportunities for Translational Research9
抗EGFR治疗在转移性结直肠癌中的应用: 合适的患者,合适的时机34
CROSS neoadjuvant chemoradiotherapy in locally advanced squamous cell cancer of the oesophagus: application beyond CROSS criteria80
Management of Nasopharyngeal Carcinoma: Is Adjuvant Therapy Needed?24
Treatment outcomes of postradiation second head and neck malignancies managed by a multidisciplinary approach89
Prognostication of Half-Life Clearance of Plasma EBV DNA in Previously Untreated Non-metastatic Nasopharyngeal Carcinoma Treated With Radical Intensity-Modulated Radiation Therapy22
Management of Advanced Gastric Cancer17
Third-line systemic treatment vs best supportive care for advanced/metastatic gastric cancer: a systematic review and meta-analysis20
Chemotherapy for Esophageal Adenocarcinoma63
Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma79
Treatment outcomes and implication of complete response on PET scan after first-line cetuximab-xelox in Chinese patients with Kras wild-type metastatic colorectal cancer53
Malignant Priapism And Germ Cell Tumour22
A prospective study on the predictive and prognostic value of baseline biomarker expressions in locoregionally advanced rectal cancer treated with neoadjuvant chemoradiation using capecitabine82
Metronomic oral cyclosphosphamide as 3rd line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma93
BRAF-mutated metastatic colorectal cancer: Is intensive therapy and metastasectomy really necessary108
Third-line Systemic Treatment In Advanced/metastatic Gastric Cancer: A Comprehensive Review32
IP Chemotherapy: Results and Risks12
Management of Colorectal Cancer: Revisiting the Role of Anti-Angiogenesis9
Discordant RAS status between primary and metastatic colorectal cancer and predicted pattern of metastases66
Hypothyroidism after radical intensity-modulated radiation therapy for nasopharyngeal carcinoma: an investigation of dosimetric predictors23
基于单病种全程管理的鼻咽癌新型 临床路径的研发与实践88
Adaptation Of International Guidelines For Metastatic Colorectal Cancer: An Asian Consensus228
Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study15
Controversies in Metastatic Colorectal Cancer41
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy: who and how?75
The feasibility and short-term efficacy of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma40
A pilot cross-sectional study on incidence of liver toxicity in cancer patients on western anti-cancer drug therapy with or without concurrent Chinese herbal medicine15
Comparison of Hyperfractionated to Conventionally Fractionated Salvage IMRT for Locoregionally Advanced Recurrent Nasopharyngeal Carcinoma98
Third-line systemic treatment versus best supportive care for advanced/metastatic gastric cancer: A systematic review and meta-analysis69
Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures32
Successful Analgesic use of Ketamine infusion in malignant cord compression51
Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma30
Safety and efficacy of cetuximab-XELOX combination in the first-line treatment of Kras wild-type metastatic colorectal cancer-QMH experience69
Fluoropyrimidines in metastatic gastric cancer: much of a muchness?14
Intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis: is HIPEC the only answer?114
Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - The Hong Kong experience174
Intravoxel incoherent motion MR imaging: comparison of diffusion and perfusion characteristics between nasopharyngeal carcinoma and post-chemoradiation fibrosis85
Comparison of volumetric evaluation for tumor response with RECIST for metastatic colorectal cancer with liver metastases only69
Recommendations on prevention and screening for colorectal cancer in Hong Kong87
Standard of Care for Nasopharyngeal Carcinoma (2018–2020)61
Radiomics Model to Predict Early Progression of Nonmetastatic Nasopharyngeal Carcinoma after Intensity Modulation Radiation Therapy: A Multicenter Study81
Literature Review of Traditional Chinese Medicine Herbs-Induced Liver Injury From an Oncological Perspective With RUCAM28
Real World Scenario: CROSS regimen as preoperative therapy for esophageal squamous cell carcinoma52
Impact of CAPOX or FOLFOX4 on Spleen size, Platelet Count and Liver Function when Partnered Cetuximab as First-line Treatment for KRAS Wild-type Metastatic Colorectal Cancer89
Intravoxel water diffusion heterogeneity MR imaging of nasopharyngeal carcinoma using stretched exponential diffusion model133
Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review20
Anti-EGFR Treatment in mCRC: The Right Patient at the Right Time24
Discordant RAS status between primary and metastatic colorectal cancer: pattern of metastasis and sidedness of primary tumor44
The Real-World Use of Regorafenib for Metastatic Colorectal Cancer: Multicentre Analysis of Treatment Pattern and Outcomes in Hong Kong133


TotJulAugSepOctNovDecJanFebMarAprMayJun
2015/2016890232453261831534241501644163
2016/2017979641088790914365427311713762
2017/2018121548915013712115653611412156676
2018/2019276918110016183195257219147145294676311
2019/20202601430423119159136169234224160195201151
2020/2021284941544238923663212712218118012500
Ever11303